An observational study in Transgender and Gender Incongruence, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Peking University Third Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Data about transgender medical care, especially the gender-affirming hormone therapy (GAHT) is extremely insufficient in China. Few evidence exists in the physical and psychological effects of the hormonal treatment in Chinese transgender population. CGAHT is designed to describe the social and mental condition of transgender people who are seeking for formal GAHT, and to investigate the physical and psychological effects of GAHT on this population in China.
CGAHT will be conducted in one of the main transgender medical centers in Chinese mainland. Participants who are seeking for the start of GAHT will be enrolled from clinical visitors. Before GAHT, participants will be interviewed with questionaries about their life experience, gender identity and social economic conditions. Evaluations on mental and physical health will be performed at baseline and during the GAHT. Participants will be followed up to 12 months. GAHT will be given to transgender people according to the protocol recommended by the international guideline (doi: 10.1210/jc.2017-01658) .
85 studies on the registry are indexed under Gender Dysphoria; 38 are open to participants now.
This study's planned enrollment of 240 is above the median of 100 across 52 observational studies indexed under Gender Dysphoria.
Browse Gender Dysphoria studies →Peking University Third Hospital is the lead sponsor of 755 studies on the registry; 275 are open to participants now.
Counted across the registry records on this site, refreshed daily.
100 transgender men, 100 trangender women, 20 healthy cisgender men and 20 healthy cisgender women
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
People whose sex assigned at birth is female but whose self-identified gender is male.
Drug: GAHT for transgender men
People whose sex assigned at birth is male but whose self-identified gender is female.
Drug: GAHT for transgender women
People whose sex assigned at birth corresponds with their self-identified gender.
Testosterone undecanoate
Also known as: Testosterone
Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)
Also known as: Feminizing drugs
Change from Baseline Insulin Sensitivity at 12 months
Insulin sensitivity will be assessed with composite insulin sensitivity index (ISI), which is calculated as 10 000/√\[(fasting glucose \[mg/dL\]) ×(fasting insulin \[μU/mL\]) × (mean glucose \[mg/dL\]) × (mean insulin \[μU/mL\])\], using 0 min, 60 min, and 120 min values of oral glucose tolerance test (OGTT). Composite ISI will be evaluated at baseline and every 6 months until 12 months of GAHT.
Time frame: 12 months
Change from Baseline Beta-cell Function at 12 months
Beta-cell function will be assessed with oral glucose tolerance test-derived disposition index (DI). First, 60 min insulinogenic index (IGI60) is calculated as (insulin60 min-insulin0 min\[μU/mL\])/(glucose60 min-glucose0 min \[mmol/L\]), using 0 min and 60 min values of OGTT. Then DI is calculated by multiplying IGI60 with composite ISI to reflect beta-cell function adjusting for the insulin sensitivity. DI will be evaluated at baseline and every 6 months until 12 months of GAHT.
Time frame: 12 months
Change from Baseline Bone Mineral Density at 12 months
Bone mineral densities (g/cm\^2) of lumber spine and hip will be evaluated by dual-energy X-ray absorptiometry at baseline and 12 months of GAHT.
Time frame: 12 months
Depression Changes from Baseline Psychological Questionnaires at 12 months
Patient Health Questionnaire will be tested at baseline and every 3 months until 12 months to understand the effects of GAHT
Time frame: 12 months
Anxiety Changes from Baseline Psychological Questionnaires at 12 months
Generalized anxiety disorder scale will be tested at baseline and every 3 months until 12 months to understand the effects of GAHT
Time frame: 12 months
Suicide Ideation Changes from Baseline Psychological Questionnaires at 12 months
Beck scale for suicide ideation will be tested at baseline and every 3 months until 12 months to understand the effects of GAHT
Time frame: 12 months
Gender Dysphoria Changes from Baseline Psychological Questionnaires at 12 months
Utrecht gender dysphoria scale will be tested at baseline and every 3 months until 12 months to understand the effects of GAHT
Time frame: 12 months
Social Exclusion Changes from Baseline at 12 months
Cyberball task will be tested at baseline and every 3 months until 12 months to understand the effects of GAHT.
Time frame: 12 months
Functional brain Change after 6 months of GAHT
Change of functional connectivity will be analyzed to understand at 6 months of GAHT.
Time frame: 6 months
Incidence of Treatment-Emergent Adverse Events
The incidence of adverse events during the 12 months of GAHT will be calculated, including thromboembolic events, drug-induced liver injury, hyperkalemia, newly diagnosed cardiovascular disease, erythrocytosis and newly diagnosed tumor.
Time frame: Up to 12 months
Change from Baseline Body Mass Index at 12 months
Body mass index is calculated as \[weight (kg) / height (m)\^2\], which will be evaluated at baseline and every 3 months until 12 months of GAHT.
Time frame: 12 months
Change from Baseline Waist-hip Ratio at 12 months
Waist-hip ratio is calculated as \[waist (cm)/hip (cm)\], which will be evaluated at baseline and every 3 months until 12 months of GAHT.
Time frame: 12 months
Change from Baseline Body Composition at 12 months
Fat percentage (%) and lean mass (kg) will be assessed using the InBody S10. The body composition will be evaluated at baseline and 12 months of GAHT.
Time frame: 12 months
Change from Baseline Breast Volume of transgender women at 12 months
Breasts of transgender women will be shot in 360° with 3D photography. The volume (ml) of both sides will be measured by the image analysis at baseline and every 6 months until 12 months of GAHT.
Time frame: 12 months
Change from Baseline Homeostatic Model Assessment Index (HOMA-IR) at 12 months
HOMA-IR is calculated as \[(fasting insulin \[µU/mL\] × fasting glucose \[mmol/L\])/22.5\]. HOMA-IR will be evaluated at baseline and every 6 months until 12 months of GAHT.
Time frame: 12 months
Change from Baseline Homeostatic Model Assessment of Beta-cell function (HOMA-β) at 12 months
HOMA-β is calculated as \[20 × (fasting insulin \[μU/mL\]) × (fasting glucose -3·5 \[mmol/L\])\]. HOMA-β will be evaluated at baseline and every 6 months until 12 months of GAHT.
Time frame: 12 months
Change from Baseline Serum Uric Acid at 12 months
Serum Uric Acid levels (μmol/l) will be evaluated at baseline and every 3 months until 12 months of GAHT.
Time frame: 12 months
Comparison of Transgender and Cisgender Functional Brain Patterns
Functional connectivity will be compared at baseline to understand the brain patterns of transgender.
Time frame: At baseline
Comparison of Transgender and Cisgender Cognitive Ability
Performance of mental rotation task of transgender and cisgender will be compared at baseline to understand the difference.
Time frame: At baseline
Plan to share: Undecided — Dataset is available from the corresponding author on reasonable request.
No publications or documents are linked to this record.
Started Apr 2022 (actual). Primary completion is estimated for Dec 2027, 68 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University Third Hospital →